TNF and colitis: The European Crohn’s and Colitis Organization and Asian Organization for Crohn’s and Colitis suggest that anti-TNF-alpha agents were withheld when active TB infection is diagnosed during the drug administration.[4,6,7] However, the British guideline contrarily recommends that anti-TNF-alpha agents should be continued if clinically indicated.[5] Thus, there is little evidence of the risk of active TB infection by immunosuppressive therapies, including anti-TNF-alpha agents.